Second-line chemotherapy in malignant pleural mesothelioma

Results of a retrospective multicenter survey

P. A. Zucali, M. Simonelli, G. Michetti, M. Tiseo, G. L. Ceresoli, E. Collovà, A. Follador, M. Lo Dico, A. Moretti, F. De Vincenzo, E. Lorenzi, M. Perrino, L. Giordano, G. Farina, A. Santoro, M. Garassino

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

The pemetrexed-cisplatin chemotherapy is standard of care in first-line (FL) treatment of malignant pleural mesothelioma (MPM). The second-line (SL) chemotherapy is considered, but the optimal treatment has not been defined yet. The aim of this study was to evaluate the clinical outcomes of SL-therapy in a series of MPM-patients included in a retrospective multicenter database. Clinical records of MPM-patients who received SL-treatment from 1996 to 2008 were reviewed. Study endpoints were response, overall-survival (OS), and progression-free-survival (PFS) for SL, stratified for patient characteristics, FL-outcomes, and type of SL. Out of 423 patients, 181 with full clinical data were identified. Patients' characteristics: median-age 64 years (range: 36-85); male gender 115 (63.5%); good EORTC-score 109 (60.2%); epithelial histology 135 (74.6%). After FL, 147 (81.2%) patients achieved disease-control (DC) and 45 had a time-to-progression. ≥ 12. months (TTP. ≥ 12). After SL, 95 patients (52.6%) achieved DC (21 response; 74 stable-disease); median PFS and OS were 4.3 and 8.7. months, respectively. According to multivariate analysis, DC after SL-therapy was significantly related to pemetrexed-based treatment (OR: 2.46; p=. 0.017) and FL-TTP. ≥ 12 (OR: 3.50; p=. 0.006). PFS was related to younger age (

Original languageEnglish
Pages (from-to)360-367
Number of pages8
JournalLung Cancer
Volume75
Issue number3
DOIs
Publication statusPublished - Mar 2012

Fingerprint

Drug Therapy
Pemetrexed
Disease-Free Survival
Therapeutics
Survival
Standard of Care
Malignant Mesothelioma
Surveys and Questionnaires
Cisplatin
Histology
Multivariate Analysis
Databases
thymidine 5'-triphosphate

Keywords

  • Disease control
  • Malignant pleural mesothelioma
  • Pemetrexed
  • Progression-free survival
  • Re-treatment
  • Second-line therapy

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Second-line chemotherapy in malignant pleural mesothelioma : Results of a retrospective multicenter survey. / Zucali, P. A.; Simonelli, M.; Michetti, G.; Tiseo, M.; Ceresoli, G. L.; Collovà, E.; Follador, A.; Lo Dico, M.; Moretti, A.; De Vincenzo, F.; Lorenzi, E.; Perrino, M.; Giordano, L.; Farina, G.; Santoro, A.; Garassino, M.

In: Lung Cancer, Vol. 75, No. 3, 03.2012, p. 360-367.

Research output: Contribution to journalArticle

Zucali, PA, Simonelli, M, Michetti, G, Tiseo, M, Ceresoli, GL, Collovà, E, Follador, A, Lo Dico, M, Moretti, A, De Vincenzo, F, Lorenzi, E, Perrino, M, Giordano, L, Farina, G, Santoro, A & Garassino, M 2012, 'Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey', Lung Cancer, vol. 75, no. 3, pp. 360-367. https://doi.org/10.1016/j.lungcan.2011.08.011
Zucali, P. A. ; Simonelli, M. ; Michetti, G. ; Tiseo, M. ; Ceresoli, G. L. ; Collovà, E. ; Follador, A. ; Lo Dico, M. ; Moretti, A. ; De Vincenzo, F. ; Lorenzi, E. ; Perrino, M. ; Giordano, L. ; Farina, G. ; Santoro, A. ; Garassino, M. / Second-line chemotherapy in malignant pleural mesothelioma : Results of a retrospective multicenter survey. In: Lung Cancer. 2012 ; Vol. 75, No. 3. pp. 360-367.
@article{53c19915b0854ce88451ad5996cb5a32,
title = "Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey",
abstract = "The pemetrexed-cisplatin chemotherapy is standard of care in first-line (FL) treatment of malignant pleural mesothelioma (MPM). The second-line (SL) chemotherapy is considered, but the optimal treatment has not been defined yet. The aim of this study was to evaluate the clinical outcomes of SL-therapy in a series of MPM-patients included in a retrospective multicenter database. Clinical records of MPM-patients who received SL-treatment from 1996 to 2008 were reviewed. Study endpoints were response, overall-survival (OS), and progression-free-survival (PFS) for SL, stratified for patient characteristics, FL-outcomes, and type of SL. Out of 423 patients, 181 with full clinical data were identified. Patients' characteristics: median-age 64 years (range: 36-85); male gender 115 (63.5{\%}); good EORTC-score 109 (60.2{\%}); epithelial histology 135 (74.6{\%}). After FL, 147 (81.2{\%}) patients achieved disease-control (DC) and 45 had a time-to-progression. ≥ 12. months (TTP. ≥ 12). After SL, 95 patients (52.6{\%}) achieved DC (21 response; 74 stable-disease); median PFS and OS were 4.3 and 8.7. months, respectively. According to multivariate analysis, DC after SL-therapy was significantly related to pemetrexed-based treatment (OR: 2.46; p=. 0.017) and FL-TTP. ≥ 12 (OR: 3.50; p=. 0.006). PFS was related to younger age (",
keywords = "Disease control, Malignant pleural mesothelioma, Pemetrexed, Progression-free survival, Re-treatment, Second-line therapy",
author = "Zucali, {P. A.} and M. Simonelli and G. Michetti and M. Tiseo and Ceresoli, {G. L.} and E. Collov{\`a} and A. Follador and {Lo Dico}, M. and A. Moretti and {De Vincenzo}, F. and E. Lorenzi and M. Perrino and L. Giordano and G. Farina and A. Santoro and M. Garassino",
year = "2012",
month = "3",
doi = "10.1016/j.lungcan.2011.08.011",
language = "English",
volume = "75",
pages = "360--367",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Second-line chemotherapy in malignant pleural mesothelioma

T2 - Results of a retrospective multicenter survey

AU - Zucali, P. A.

AU - Simonelli, M.

AU - Michetti, G.

AU - Tiseo, M.

AU - Ceresoli, G. L.

AU - Collovà, E.

AU - Follador, A.

AU - Lo Dico, M.

AU - Moretti, A.

AU - De Vincenzo, F.

AU - Lorenzi, E.

AU - Perrino, M.

AU - Giordano, L.

AU - Farina, G.

AU - Santoro, A.

AU - Garassino, M.

PY - 2012/3

Y1 - 2012/3

N2 - The pemetrexed-cisplatin chemotherapy is standard of care in first-line (FL) treatment of malignant pleural mesothelioma (MPM). The second-line (SL) chemotherapy is considered, but the optimal treatment has not been defined yet. The aim of this study was to evaluate the clinical outcomes of SL-therapy in a series of MPM-patients included in a retrospective multicenter database. Clinical records of MPM-patients who received SL-treatment from 1996 to 2008 were reviewed. Study endpoints were response, overall-survival (OS), and progression-free-survival (PFS) for SL, stratified for patient characteristics, FL-outcomes, and type of SL. Out of 423 patients, 181 with full clinical data were identified. Patients' characteristics: median-age 64 years (range: 36-85); male gender 115 (63.5%); good EORTC-score 109 (60.2%); epithelial histology 135 (74.6%). After FL, 147 (81.2%) patients achieved disease-control (DC) and 45 had a time-to-progression. ≥ 12. months (TTP. ≥ 12). After SL, 95 patients (52.6%) achieved DC (21 response; 74 stable-disease); median PFS and OS were 4.3 and 8.7. months, respectively. According to multivariate analysis, DC after SL-therapy was significantly related to pemetrexed-based treatment (OR: 2.46; p=. 0.017) and FL-TTP. ≥ 12 (OR: 3.50; p=. 0.006). PFS was related to younger age (

AB - The pemetrexed-cisplatin chemotherapy is standard of care in first-line (FL) treatment of malignant pleural mesothelioma (MPM). The second-line (SL) chemotherapy is considered, but the optimal treatment has not been defined yet. The aim of this study was to evaluate the clinical outcomes of SL-therapy in a series of MPM-patients included in a retrospective multicenter database. Clinical records of MPM-patients who received SL-treatment from 1996 to 2008 were reviewed. Study endpoints were response, overall-survival (OS), and progression-free-survival (PFS) for SL, stratified for patient characteristics, FL-outcomes, and type of SL. Out of 423 patients, 181 with full clinical data were identified. Patients' characteristics: median-age 64 years (range: 36-85); male gender 115 (63.5%); good EORTC-score 109 (60.2%); epithelial histology 135 (74.6%). After FL, 147 (81.2%) patients achieved disease-control (DC) and 45 had a time-to-progression. ≥ 12. months (TTP. ≥ 12). After SL, 95 patients (52.6%) achieved DC (21 response; 74 stable-disease); median PFS and OS were 4.3 and 8.7. months, respectively. According to multivariate analysis, DC after SL-therapy was significantly related to pemetrexed-based treatment (OR: 2.46; p=. 0.017) and FL-TTP. ≥ 12 (OR: 3.50; p=. 0.006). PFS was related to younger age (

KW - Disease control

KW - Malignant pleural mesothelioma

KW - Pemetrexed

KW - Progression-free survival

KW - Re-treatment

KW - Second-line therapy

UR - http://www.scopus.com/inward/record.url?scp=84856577906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856577906&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2011.08.011

DO - 10.1016/j.lungcan.2011.08.011

M3 - Article

VL - 75

SP - 360

EP - 367

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 3

ER -